Study On The Value Of Combined Detection Of Six Tumor Markers In The Diagnosis Of Lung Cancer

background and objectiveLung cancer is a malignant tumor that occurs in the bronchial epithelium,also known as bronchial cancer.In the past 60 years,the incidence of lung cancer has been reported to increase significantly in many national regions.It has become the first among the incidence of male cancer patients,and the incidence rate in women has also increased rapidly,accounting for the second or third place of common malignant tumors in women.At present,it is basically clear that lung cancer is caused by multi-gene synergistic,multi-step,multi-stage development,that is,the same gene has different expressions in different stages of development of various tumors,and the same type of tumor shows the mutual coordination of multiple genes.Tumor markers are an important means of examination,providing effective evidence for clinical diagnosis and treatment,and for reducing the cost of screening for patients under simple and economical conditions.With the advancement of existing examination methods,tumor markers have become an important auxiliary examination method.The clinical value of serum tumor markers detection in lung cancer patients is intended to provide reference for clinical diagnosis and treatment.What are the markers at each stage of lung cancer,and whether the tumor markers are mainly passive or active,the tumor markers are distributed in which organs and tissues,tumor markers and tumor stages are graded.Relationship,tumor markers and efficacy and prognosis.Clinically,the primary treatment of lung cancer is mainly based on the clinical stage of NCCN.This stage mainly relies on imaging examination.The evaluation of treatment effect mainly relies on imaging examination.This study aims to screen the different genders through retrospective research.Age,pathological type and staged lung cancer patients,compare their tumor marker specificity and dynamic changes,and use statistical analysis to explore the clinical value of detection of tumor markers in lung cancer patients,for clinical diagnosis and treatment,for patients to reduce screening The fee provides valid evidence.To investigate tumor markers carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),carbohydrate antigen 199(CA199,carbohydrate antigen 125(CA125),cytokeratin 21-1(CYfra21-1),Differences in expression of lactate dehydrogenase(LDH)in different types oflung cancer and evaluation of the combined tumor markers detection in the assist diagnosis of lung cancer.MethodsSix serum markers were detected by electrochemiluminescence and enzymatic method in 291 patients with lung cancer,200 patients with benign lung disease and 215 healthy subjects.ResultsThe levels of 6 serum tumor markers in lung cancer patients were significantly higher than those in lung benign and healthy subjects(P<0.05).The levels of CYfra21-1 and CA199 were significantly higher in men than in women,in squamous cell carcinoma.The positive rate was higher than that of adenocarcinoma(P<0.05).The expression level of LDH and NSE in small cell lung cancer was significantly higher than that in the group of non-small cell lung cancer.CA199 and CEA levels were significantly lower in small cell lung cancer than in non-small cell lung cancer(P<0.05);CEA and LDH were significantly different between adenocarcinoma and squamous cell carcinoma(P<0.05);the elevation of serum markers was positively correlated with lung cancer TNM staging(P<0.05);sensitivity of combined test results And accuracy is significantly higher than single detection.ConclusionSix serum markers are abnormally high in lung cancer patients and have significant correlation with TNM staging.At the same time,combined detection can significantly improve the sensitivity and positive rate of lung cancer assisted diagnosis,can make up for the deficiency of single test,and provide a basis for optimizing treatment.